Clinical trial · Interventional
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
NCT03278275CI-TRIAL-00059388completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| One injection of 68Ga-NOTA-AE105 | Drug | — | UNRESOLVED |
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- uPAR PET/CT
- description
- One injection of the radioligand 68Ga-NOTA-AE105
- interventionNames
- Drug: One injection of 68Ga-NOTA-AE105
- Device: PET/CT
Primary outcomes (1)
- measure
- uPAR PET/CT imaging of patients with neuroendocrine tumors
- timeFrame
- 1 hour
- description
- The radioligand 68Ga-NOTA-AE105 can be used to visualize neuroendocrine tumors (grade G1-G3)
Secondary outcomes (2)
- measure
- uPAR PET/CT prognostic factor for progression free survival
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with gastro-entero-pancreatic Neuroendocrine Tumors (GEP-NET; grade: G1-G3) or broncho-pulmonary NET. * WHO performance status 0-2 * Must be able to read and understand the patient information in Danish and to give informed consent Exclusion Criteria: * Pregnancy * Breast-feeding * Weight more than the maximum weight limit for the PET/CT bed of the scanner (140 kg) * History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E\[c(RGDyK)\]2 * In case of broncho-pulmonary NET, the subtype must not be small cell lung cancer (SCLC)
References
Publications (0)
Data not yet available
No reference posted for this study.